Related Experiment Video
Updated: May 28, 2025

Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Nonislet Cell Tumor Hypoglycemia: A Rare Paraneoplastic Syndrome
Aishwarya Gaur1, Shyam Sunder2, Prabhat Narain Sharma3
1Resident, DNB Medicine, Department of General Medicine, Employees' State Insurance Corporation Model Hospital, Jaipur, Rajasthan, India.
Abstract:
Nonislet cell tumor hypoglycemia (NICTH) is a rare and underreported cause of hypoglycemia due to excessive production of insulin-like growth factor 2 (IGF-2) and its intermediate forms, which activate the insulin receptor. Typically, certain malignancies can cause NICTH, usually as a paraneoplastic syndrome. Diagnosis requires a raised IGF-2/IGF-1 ratio. Surgery forms the cornerstone of management, while glucocorticoids are an alternative when surgery is not possible. We present a unique case of a 27-year-old male, who was a follow-up case of chronic hepatitis B infection and presented with a gall bladder fossa mass and recurrent, severe episodes of hypoglycemia. Workup revealed low insulin and C-peptide and suppressed IGF-1 with normal pituitary function. Clinicians should consider the possible diagnosis of NICTH when laboratory and immunohistochemical (IHC) data do not support more common causes, such as insulinoma.
Related Concept Videos
Hypoglycemia and Glucagon
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Glinides
Insulin Secretory Vesicles

